LigaChem Biosciences Inc.
Financials
Valuation Metrics
LigaChem Biosciences Inc.'s Market Cap is ₩3.0T. At end of 2025 it was ₩6.4T. Ranked #154 of 2,421 in KR market (top 6%), #22 of 1,640 on KOSDAQ (top 1%), #12 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 5%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 3.02T KRW | KR#154/2,421 Sec#12/231 |
| Revenue | 98.78B KRW | KR#1,425/2,421 Sec#88/231 |
| Net Income | -181.37B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 701.81B KRW | KR#611/2,421 Sec#34/231 |
| Net Assets | 541.12B KRW | KR#482/2,421 Sec#30/231 |
| Employees | 174 | KR#1,196/2,421 Sec#99/231 |
| Value | ||
| P/B | 5.59x | KR#2,269/2,421 Sec#195/231 |
| P/S | 30.62x | KR#2,358/2,421 Sec#191/231 |
| FCF Yield | -4.22% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -33.52% | KR#2,212/2,421 Sec#185/231 |
| ROA | -25.84% | KR#2,285/2,421 Sec#191/231 |
| Op. Margin | -208.25% | KR#2,337/2,421 Sec#184/231 |
| Revenue Growth | -33.38% | KR#2,236/2,421 Sec#199/231 |
| Financial Health | ||
| Debt Ratio | 29.70% | KR#585/2,421 Sec#66/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -127.58B KRW | KR#2,150/2,421 Sec#212/231 |
| Cash | 98.65B KRW | KR#474/2,421 Sec#23/231 |
| Current Ratio | 9.37x | KR#111/2,421 Sec#27/231 |
| Performance | ||
| 1Y Return | -44.69% | KR#1,939/2,421 Sec#166/231 |
| 1M Return | -21.74% | KR#2,312/2,421 Sec#211/231 |
| From 52W High | -63.69% | KR#1,994/2,421 Sec#161/231 |
| 1Y MDD | -63.51% | KR#1,665/2,421 Sec#138/231 |
| Trading | ||
| Volume | 99,508 shares | KR#785/2,421 Sec#73/231 |
| Trading Value | 8.19B KRW | KR#278/2,421 Sec#24/231 |
| Foreign Own. | 12.63% | KR#391/2,421 Sec#28/231 |
| Per Share | ||
| EPS | -4,899 KRW | KR—/2,421 Sec—/231 |
| BPS | 14,617 KRW | KR#715/2,421 Sec#48/231 |
Company Info
LegoChem Biosciences, established in 2006 and headquartered in Yuseong-gu, Daejeon, is a research-oriented pharmaceutical company listed on KOSDAQ in 2013. The company developed the medicinal chemistry-based original Antibody-Drug Conjugate (ADC) technology named ConjuALL, driving global commercialization through ADC anticancer drug research and development and technology transfer. Through "Beyond ADC" research, it focuses on developing bispecific antibody ADCs, immuno-oncology drugs, and combination therapies, while also securing stable revenue from medical device and consumable sales.